Clinical Trials Logo

Covert Hepatic Encephalopathy clinical trials

View clinical trials related to Covert Hepatic Encephalopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03585257 Completed - Cirrhosis Clinical Trials

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

HEAL
Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

Patients with continued cognitive impairment after episodes of HE have few options beyond lactulose and rifaximin in the US. Therefore using IV albumin in a randomized, double-blind, placebo-controlled trial, which could beneficially impact inflammation, could be an additional approach to improve cognition. This 6 week trial will study changes in cognition, HRQOL and inflammation in patients with covert HE after prior overt HE using multiple IV albumin infusions vs. placebo.

NCT ID: NCT03077217 Completed - Clinical trials for Covert Hepatic Encephalopathy

Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

Several studies have been showed that rifaximin can improve cognitive functions, driving simulator performance and health-related quality of life in patients with minimal hepatic encephalopathy. The aim of this prospective randomized open controlled study was to evaluate the efficacy and safety of rifaximin at different doses for the treatment of covert hepatic encephalopathy.